About Antibe Thera
Antibe Thera is a Healthcare company based in Toronto (Canada) founded in 2010, and was acquired by Taro in January 2025. Therapeutics for inflammation, pain, and vascular dysfunction are developed. Antibe Thera has completed 1 acquisition, including Citagenix. Its chief executive, as recorded, is Daniel Legault. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Antibe Therapeutics Inc.
Company details
Antibe was founded in 2010 in Toronto, Canada, within the biotechnology sector. Focus is placed on diseases involving inflammation, pain, or vascular dysfunction. Operations center on drug design, where existing proven drugs are chemically linked to a hydrogen sulfide-releasing moiety. This platform leverages hydrogen sulfide as a modulator for cellular processes, including neuromodulation, immunomodulation, and vasodilation. Development targets therapeutic applications in these areas.
- Headquarters Toronto, Canada
- Stage Acquired
- SectorsHealthcare
- Website antibethera.com
- Acquired by Taro (Jan 2025)
- Legal Name Antibe Therapeutics Inc.
- Latest Funding Round$283.32K (USD), Post-IPO
Aug 2019
- InvestorsKnight Therapeutics
& 2 more
- Investments & Acquisitions
- Acquired byTaro
(Jan 2025)
Funding Insights of Antibe Thera
- Total Rounds 9
- Last Round Post-IPO — $283,319
- First Round $55,000
(Aug 2013)
- Investors Count 2
All 9 funding rounds of Antibe Thera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2019 | $283,319 | Post-IPO | – | – | – |
| Dec 2018 | $1.6M | Post-IPO | – | – | – |
| Dec 2016 | $2.43M | Post-IPO | – | – | – |
| Jun 2016 | $486,500 | Post-IPO | – | – | – |
| Jun 2016 | $968,500 | Post-IPO | – | – | – |
| Feb 2016 | $460,000 | Post-IPO | – | – | – |
| Nov 2015 | $2.6M | Post-IPO | – | – | |
| Mar 2014 | $2.71M | Post-IPO | – | – | – |
| Aug 2013 | $55,000 | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in Antibe Thera
Antibe Thera has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Knight Therapeutics, Taro Pharmaceutical Industries and Bloom Burton & Co.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Prescription pharmaceuticals are acquired, licensed, and commercialized by the company. | 2014 | gud-knight.com | Westmount, Canada | |
Investment opportunities in healthcare are facilitated by Bloom Burton. | bloomburton.com | Toronto, Canada | ||
Taro Pharmaceutical Industries is engaged in developing and distributing pharmaceuticals. | 1950 | taro.com | Haifa, Israel |
Investor details for Antibe Thera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Antibe Thera
1 people are tracked at Antibe Thera (1 in leadership).
| Name | Role | Group |
|---|---|---|
Daniel Legault | CEO | Leadership |
Complete people profiles for Antibe Thera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Antibe Thera
Antibe Thera has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Citagenix.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Bone regeneration products are developed for orthopedic and dental applications. | citagenix.com | Laval, Canada | 1997 | Oct 2015 | $400,000 |
Complete acquisition details for Antibe Thera
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Antibe Thera
6 dated milestones of Antibe Thera across 15 years, from founding to its latest funding, stage changes and deals.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Antibe Thera
Complete news archive for Antibe Thera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antibe Thera
Antibe Thera was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Antibe Thera is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Daniel Legault is the CEO of Antibe Thera, as recorded in our data.
Antibe was founded in 2010 in Toronto, Canada, within the biotechnology sector. Focus is placed on diseases involving inflammation, pain, or vascular dysfunction. Operations center on drug design, where existing proven drugs are chemically linked to a hydrogen sulfide-releasing moiety. This platform leverages hydrogen sulfide as a modulator for cellular processes, including neuromodulation, immunomodulation, and vasodilation. Development targets therapeutic applications in these areas.
Antibe Thera has made 1 acquisition, including Citagenix.
Antibe Thera has 3 investors. Key investors include Knight Therapeutics, Taro Pharmaceutical Industries, and Bloom Burton & Co.
Antibe Thera operates through Antibe Therapeutics Inc..
Yes. Antibe Thera was acquired by Taro in January 2025.